- Home
- AIM
as 07-26-2024 4:00pm EST
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.
| Founded: | 1966 | Country: | United States |
| Employees: | N/A | City: | OCALA |
| Market Cap: | 23.4M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 205.7K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.64 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.31 - $0.72 | Next Earning Date: | 08-13-2024 |
| Revenue: | $193,000 | Revenue Growth: | 23.72% |
| Revenue Growth (this year): | -35.84% | Revenue Growth (next year): | 1287.20% |
Stock Insider Trading Activity of AIM ImmunoTech Inc. (AIM)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Equels Thomas K | AIM | CEO & President | May 6 '24 | Buy | $0.41 | 61,729 | $25,000.25 | 778,184 | SEC Form 4 |
| Rodino Peter W III | AIM | COO, Secretary, Gen. Counsel | May 6 '24 | Buy | $0.41 | 30,865 | $12,500.33 | 212,583 | SEC Form 4 |
| BRYAN NANCY | AIM | Director | Mar 21 '24 | Buy | $0.39 | 38,462 | $15,000.18 | 38,462 | SEC Form 4 |
| Equels Thomas K | AIM | CEO & President | Mar 15 '24 | Buy | $0.33 | 75,758 | $25,000.14 | 716,455 | SEC Form 4 |
| Rodino Peter W III | AIM | COO, Secretary, Gen. Counsel | Mar 15 '24 | Buy | $0.33 | 37,879 | $12,500.07 | 181,718 | SEC Form 4 |
| APPELROUTH STEWART | AIM | Director | Mar 15 '24 | Buy | $0.33 | 90,910 | $30,000.30 | 239,765 | SEC Form 4 |
Latest AIM ImmunoTech Inc. News
AIM Breaking Stock News: Dive into AIM Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
AIM Announces New Positive Data on Ampligen’s Anti-Tumor Potential When Used as Part of a Combination Therapy
GlobeNewswire
24 days ago
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
GlobeNewswire
2 months ago
AIM ImmunoTech to Participate in the Virtual Investor Pitch Conference
Motley Fool
2 months ago
Better AI Stock: Palantir vs. Snowflake
Motley Fool
2 months ago
Is Now the Time to Buy 3 of the S&P 500's Highest-Yielding Dividend Stocks?
Motley Fool
2 months ago
BigBear.ai Stock: Buy, Sell, or Hold?
AFP
2 months ago
Indonesia's first Olympic gymnast encourages others to 'dream higher'
Motley Fool
2 months ago
Where Will CrowdStrike Stock Be in 1 Year?
Compare AIM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AIM AIM ImmunoTech Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.